ETFs that look at a subsector of biotech have significantly outperformed broader biotech funds this year.
Which biotech/genomics ETF is the better play?
Plus, several funds undergo name and index changes.
Plus, iShares lowered expense ratios on two of its ETFs.
A review of fund flows and key trends around microcaps, uranium and biotech.
Interest rates hit their highest levels in a year on Wednesday, putting pressure on long-duration assets.
The new fund targets themes demonstrating disruptive innovation.
Not every viable ETF gathers large amounts of assets right out of the gate.
Global X's new telemedicine fund proves to be the right ETF for the right moment.